Refractory immune thrombocytopenic purpura: Current strategies for investigation and management

British Journal of Haematology

Volumn 143, Issue 1, 2008, Pages 16-26

  Psaila, Bethan ^a,b   Bussel, James B ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

Bleeding; Chronic immune thrombocytopenic purpura; Platelet; Thrombopoiesis; Thrombopoietin

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DANAZOL; DAPSONE; ELTROMBOPAG; GLUCOCORTICOID; IMMUNOGLOBULIN; LEVONORGESTREL; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; REMIPLISTIM; RITUXIMAB; THROMBOPOIETIN RECEPTOR; VINCA ALKALOID; VINCRISTINE;

ANEMIA; AUTOIMMUNE HEMOLYTIC ANEMIA; BLEEDING; CHILL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE DURATION; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG FATALITY; DRUG INTERMITTENT THERAPY; FEVER; HEADACHE; HELICOBACTER PYLORI; HEMOLYSIS; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOGENETICS; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; LABORATORY TEST; LOW DRUG DOSE; MENORRHAGIA; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SPLENECTOMY; THROMBOCYTE COUNT; THROMBOCYTOPOIESIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VIRUS LOAD;

ANTIBODIES, MONOCLONAL; CYCLOPHOSPHAMIDE; DIAGNOSIS, DIFFERENTIAL; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOSUPPRESSIVE AGENTS; PURPURA, THROMBOCYTOPENIC; QUALITY OF LIFE; RECEPTORS, THROMBOPOIETIN; RHO(D) IMMUNE GLOBULIN; SPLENECTOMY; THROMBOCYTOPENIA;

EID: 51249106397     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2008.07275.x     Document Type: Review

References (77)

1. Aledort, L.M., Hayward, C.P., Chen, M.G., Nichol, J.L. Bussel, J. (2004) Prospective screening of 205 patients with ITP, including diagnosis, serological markers, and the relationship between platelet counts, endogenous thrombopoietin, and circulating antithrombopoietin antibodies. American Journal of Hematology, 76, 205 213.
2. Andemariam, B., Psaila, B. Bussel, J.B. (2007) Novel thrombopoietic agents. Hematology/The Education Program of the American Society of Hematology, 2007, 106 113.
3. Arnold, D.M. Kelton, J.G. (2007) Current options for the treatment of idiopathic thrombocytopenic purpura. Seminars in Hematology, 44, S12 S23.
4. Arnold, D., Dentali, F., Crowther, M., Meyer, R., Cook, R., Siqouin, C., Fraser, G., Lim, W. Kelton, J.G. (2007) Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombcytopenic purpura. Annals of Internal Medicine, 146, 25 33.
5. Bader-Meunier, B., Proulle, V., Trichet, C., Debray, D., Gabolde, M., Yvart, J. Dreyfus, M. (2003) Misdiagnosis of chronic thrombocytopenia in childhood. Journal of Pediatric Hematology/oncology, 25, 548 552.
6. Ballem, P.J., Segal, G.M., Stratton, J.R., Gernsheimer, T., Adamson, J.W. Slichter, S.J. (1987) Mechanisms of thrombocytopenia in chronic autoimmune thrombocytopenic purpura. Evidence of both impaired platelet production and increased platelet clearance. Journal of Clinical Investigation, 80, 33 40.
7. Bartley, T.D., Bogenberger, J., Hunt, P., Li, Y.S., Lu, H.S., Martin, F., Chang, M.S., Samal, B., Nichol, J.L. Swift, S. (1994) Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor Mpl. Cell, 77, 1117 1124.
8. Boruchov, D.M., Gururangan, S., Driscoll, M.C. Bussel, J.B. (2007) Multiagent induction and maintenance therapy for patients with refractory immune thrombocytopenic purpura (ITP). Blood, 110, 3526 3531.
9. Bussel, J.B. (2007) Novel thrombopoietic agents: preliminary activity, potential benefit. The Journal of Supportive Oncology, 5, 63 84.
10. Bussel, J.B., Pham, L.C., Aledort, L. Nachman, R. (1988) Maintenance treatment of adults with chronic refractory immune thrombocytopenic purpura using repeated intravenous infusions of gammaglobulin. Blood, 72, 121 127.
11. Bussel, J.B., Kuter, D.J., George, J.N., McMillan, R., Aledort, L.M., Conklin, G.T., Lichtin, A.E., Lyons, R.M., Nieva, J., Wasser, J.S., Wiznitzer, I., Kelly, R., Chen, C.F. Nichol, J.L. (2006) AMG 531, a thrombopoiesis- stimulating protein, for chronic ITP. New England Journal of Medicine, 355, 1672 1681.
12. Bussel, J.B., Cheng, G., Saleh, M.N., Psaila, B., Kovaleva, L., Meddeb, B., Kloczko, J., Hassani, H., Mayer, B., Stone, N.L., Arning, M., Provan, D. Jenkins, J.M. (2007a) Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. New England Journal of Medicine, 357, 2237 2247.
13. Bussel, J.B., Provan, D., Shamsi, T., Cheng, G., Kovaleva, L., Stone, N.L., Mayer, B., Poulin, R. Arning, M. (2007b) Eltrombopag raises platelet count and reduces bleeding compared to placebo during short-term treatment in chronic idiopathic thrombocytopenic purpura: a phase III study. Haematologica/The Hematology Journal 92 (Suppl. 2 143 abstract 0390.
14. Bussel, J.B., Kuter, D.J., de Wolf, J.T.M., Guthrie, Jr., T.H., Newland, A., Wasser, J.S., Hamburg, S.I., Bjorkquist, L., Guo, M. Nichol, J.L. (2007c) Long-term dosing of AMG531 in thrombocytopenic patients with immune thrombocytopenic purpura: 2-year update. Blood (ASH Annual Meeting Abstracts), 110, 568.
15. Bussel, J.B., Cheng, G., Kovaleva, L., Saleh, M.N., Meddib, B., Mayer, B., Fraser, J.L. Aivado, M. (2007d) Long-term safety and efficacy of oral eltrombopag for the treatment of subjects with idiopathic thrombocytopenic purpura (ITP): preliminary data from the EXTEND study. Blood (ASH Annual Meeting Abstracts), 110, 566.
16. Chagraoui, H., Komura, E., Tulliez, M., Giraudier, S., Vainchenker, W. Wendling, F. (2002) Prominent role of TGF-beta 1 in thrombopoietin-induced myelofibrosis in mice. Blood, 100, 3495 3503.
17. Chang, M., Nakagawa, P.A., Williams, S.A., Schwartz, M.R., Imfeld, K.L., Buzby, J.S. Nugent, D.J. (2003) Immune Thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitro. Blood, 102, 887 895.
18. Cines, D.B. Bussel, J.B. (2005) How I treat idiopathic thrombocytopenic purpura (ITP). Blood, 106, 2244 2251.
19. Cines, D.B., Cassileth, P.A. Kiss, J.E. (1985) Danazol therapy in myelodysplasia. Annals of Internal Medicine, 103, 58 60.
20. Cooper, N., Woloski, B.M., Fodero, E.M., Novoa, M.V., Leber, M., Beer, J.H. Bussel, J.B. (2002) Does treatment with intermittent infusions of anti-D allow a proportion of adults with recently diagnosed immune thrombocytopenic purpura to avoid splenectomy? Blood, 99, 1922 1927.
21. Cooper, N., Stasi, R., Cunningham-Rundles, C., Feuerstein, M.A., Leonard, J.P., Amadori, S. Bussel, J. (2004) The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. British Journal Of Haematology, 125, 232 239.
22. Cooper, N., Evangelista, M.L., Amadori, S. Stasi, R. (2007) Should rituximab be used before or after splenectomy in patients with immune thrombocytopenic purpura? Current Opinion in Hematology, 14, 642 646.
23. DiMaggio, D.M. Bussel, J.B. (2007) The role of cytomegalovirus in immune thrombocytopenic purpura. Blood (ASH Annual Meeting Abstracts), 110, 2101.
24. Dolan, J.P., Sheppard, B.C. DeLoughery, T.G. (2007) Splenectomy for immune thrombocytopenic purpura: surgery for the 21st century. American Journal of Hematology, 83, 93 96.
25. El-Najjar, I., Rule, S.A.J. Nokes, T.J.C. (2006) A fixed, low dose of anti-CD20 antibody (Rituximab) is an effective treatment for patients with chronic immune thrombocytopenia. British Journal Haematology, 133, 79 (Abstract 196).
26. George, J.N. (2006) Management of patients with refractory immune thrombocytopenic purpura. Journal of Thrombosis and Haemostasis, 4, 1664 1672.
27. George, J., Raskob, G., Vesely, S., Moore, D.J., Lyons, R.M., Cobos, E., Towell, B., Klug, P. Guthrie, T. (2003) Initial management of immune thrombocytopenic purpura in adults: a randomized controlled trial comparing intermittent anti-D with routine care. American Journal of Hematology, 73, 135 140.
28. Gernsheimer, T., Stratton, J., Ballem, P.J. Slichter, S.J. (1989) Mechanisms of response to treatment in autoimmune thrombocytopenic purpura. New England Journal of Medicine, 320, 974 980.
29. Godeau, B., Provan, D. Bussel, J. (2007) Immune thrombocytopenic purpura in adults. Current Opinion in Hematology, 14, 535 556.
30. Gu, J., Lu, L., Xu, R. Chen, X. (2002) Plasma thrombopoietin levels in patients with aplastic anemia and idiopathic thrombocytopenic purpura. Chinese Medical Journal, 115, 983 986.
31. Houwerzijl, E.J., Blom, N.R., van der Want, J.J., Esselink, M.T., Koornstra, J.J., Smit, J.W., Louwes, H., Vellenga, E. de Wolf, J.T. (2004) Ultrastructural study shows morphological features of apoptosis and paraapoptosis in megakaryocytes from patietns with idiopathic thrombocytopenic purpura. Blood, 103, 500 506.
32. Kantarjian, H., Fenaux, P., Sekeres, M.A., Becker, P., Boruchov, A., Bowen, D., Larson, R., Lyons, R.M., Muus, P., Shammo, J., Ehrman, M., Hu, K. Nichol, J.L. (2007) Phase 1/2 study of AMG531 in thrombocytopenic patients with low-risk myelodysplastic syndrome: update including extended treatment. Blood (ASH Annual Meeting Abstracts), 110, 250.
33. Karpatkin, S. Charmatz, A. (1969) Heterogeneity of human platelets, I: metabolic and kinetic evidence suggestive of young and old platelets. Journal of Clinical Investigation, 48, 1073 1092.
34. Kaslow, R.A., Phair, J.P., Friedman, H.B., Lyter, D., Solomon, R.E., Dudley, J., Polk, B.F. Blackwelder, W. (1987) Infection with the human immunodeficiency virus: clinical manifestations and their relationship to immune deficiency. A report from the Multicenter AIDS Cohort Study. Annals of Internal Medicine, 107, 474 480.
35. Kojouri, K., Vesely, S.K., Terrell, D.R. George, J.N. (2004) Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood, 104, 2623 2634.
36. Kurata, Y., Curd, J.G., Tamerius, J.D. McMillan, R. (1985) Platelet-associated complement in chronic ITP. British Journal Of Haematology, 60, 723 733.
37. Kuter, D.J. (2007) New thrombopoietic growth factors. Blood, 109, 4607 4616.
38. Kuter, D.J., Bussel, J.B., Lyons, R.M., Pullarkat, V., Gernsheimer, T.G., Senecal, F.M., Aledort, L.M., George, J.N., Kessler, C.M., Sanz, M.A., Liebman, H.A., Slovick, F.T., de Wolf, J.T.M., Bourgeois, E., Guthrie, Jr., T.H., Newland, A., Wasser, J.S., Hamburg, S.I., Grande, C., Lefrere, F., Lichtin, A.E., Tarantino, M.D., Terebelo, H.R., Viallard, J.-F., Cuevas, F.J., Go, R.S., Henry, D.H., Redner, R.L., Rice, L., Schipperus, M.R., Guo, D.M. Nichol, J.L. (2008) Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet, 371, 395 403.
39. Kuwana, M. Ikeda, Y. (2006) Helicobacter pylori and immune thrombocytopenic purpura: unsolved questions and controversies. International Journal of Hematology, 84, 309 315.
40. Levy, A.S. Bussel, J.B. (2004) Immune thrombocytopenic purpura: investigation of the role of cytomegalovirus infection. British Journal Haematology, 126, 622 623.
41. Li, J., Yang, C., Xia, Y., Bertino, A., Glaspy, J., Roberts, M. Kuter, D.J. (2001) Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood, 98, 3241 3248.
42. Lok, S., Kaushansky, K., Holly, R.D., Kuijper, J.L., Lofton-Day, C.E., Oort, P.J., Grant, F.J., Heipel, M.D., Burkhead, S.K., Kramer, J.M., Bell, L.A., Sprecher, C.A., Blumberg, H., Johnson, R., Prunkard, D., Ching, A.F.T., Mathewes, S.L., Bailey, M.C., Forstrom, J.W., Buddle, M.M., Osborn, S.G., Evans, S.J., Sheppard, P.O., Presnell, S.R., Ohara, P.J., Hagen, F.S., Roth, G.J. Foster, D.C. (1994) Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo. Nature, 369, 565 568.
43. McHutchison, J.G., Dusheiko, G., Shiffman, M.L., Rodriguez-Torres, M., Sigal, S., Bourliere, M., Berg, T., Gordon, S.C., Campbell, F.M., Theodore, D., Blackman, N., Jenkins, J. Afdhal, N.H. (2007) Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. New England Journal of Medicine, 357, 2227 2236.
44. McMillan, R. Durette, C. (2004) Long-term outcomes in adults with chronic ITP after splenectomy failure. Blood, 104, 956 960.
45. McMillan, R., Bussel, J.B., George, J.N., Lalla, D. Nichol, J.L. (2008) Self-reported health-related quality of life in adults with chronic immune thrombocytopenic purpura. American Journal of Hematology, 83, 150 154.
46. Michel, M., Kreidel, F., Chapman, E.S., Zelmanovic, D. Bussel, J.B. (2005) Prognostic relevance of large-platelet counts in patients with immune thrombocytopenic purpura. Haematologica, 90, 1715 1716.
47. Musaji, A., Cormont, F., Thiron, G., Cambiaso, C. Coutelier, J. (2004) Exacerbation of autoantibody-mediated thrombocytopenic purpura by infection with mouse viruses. Blood, 104, 2102 2106.
48. Musaji, A., Meite, M., Detalle, L., Franquin, S., Cormont, F., Preat, V., Izui, S. Coutelier, J.P. (2005) Enhancement of autoantibody pathogenicity by viral infections in mouse models of anemia and thrombocytopenia. Autoimmunity Reviews, 4, 247 252.
49. Najean, Y., Rain, J.D. Billotey, C. (1997) The site of destruction of autologous 111In-labelled platelets and the efficiency of splenectomy in children and adults with idiopathic thrombocytopenic purpura: a study of 578 patients with 268 splenectomies. British Journal Haematology, 97, 547 550.
50. Newland, A. (2007) Thrombopoietin mimetic agents in the management of immune thrombocytopenic purpura. Seminars in Hematology, 44, S35 S45.
51. Newland, A., Caulier, M.T., Kappers-Klunne, M., Schipperus, M.R., Lefrere, F., Zwaginga, J.J., Christal, J., Chen, C.F. Nichol, J.L. (2006) An open-label, unit dose-finding study of AMG 531, a novel thrombopoiesis- stimulating peptibody, in patients with immune thrombocytopenic purpura. British Journal of Haematology, 135, 547 553.
52. Nomura, S., Dan, K., Hotta, T., Fujimura, K. Ikeda, Y. (2002) Effects of pegylated recombinant human megakaryocyte growth and development factor in patients with idiopathic thrombocytopenic purpura. Blood, 100, 728 730.
53. Norton, A. Roberts, I. (2006) Management of Evans syndrome. British Journal Haematology, 132, 125 137.
54. Olsson, B., Andersson, P.O., Jernas, M., Jacobsson, S., Carlsson, B., Carlsson, L.M. Wadenvik, H. (2003) T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nature Medicine, 9, 1123 1124.
55. Onel, K. Bussel, J.B. (2004) Adverse effects of estrogen therapy in a subset of women with ITP. Journal of Thrombosis and Haemostasis, 2, 670 671.
56. Panitsas, F.P., Theodoropoulou, M., Kouraklis, A., Karakantza, M., Theodorou, G.L., Zoumbos, N.C., Maniatis, A. Mouzaki, A. (2004) Adult chronic idiopathic thrombocytopenic purpura (ITP) is the manifestation of a type-1 polarized immune response. Blood, 103, 2645 2647.
57. Panzer, S. (2008) New therapeutic options for adult chronic immune thrombocytopenic purpura: a brief review. Vox Sanguinis, 94, 1 5.
58. Patel, V., Mihatov, N., Cooper, N., Stasi, R., Cunningham-Rundles, C. Bussel, J. (2006) Long term follow-up of patients with immune thrombocytopenic purpura (ITP) whose initial response to rituximab lasted a minimum of 1 year. Blood (ASH Annual Meeting Abstracts), 108, 479.
59. Porcelijn, L., Folman, C.C., Bossers, B., Huiskes, E., Overbeeke, M.A., v d Schoot, C.E., de Haas, M. von dem Borne, A.E. (1998) The diagnostic value of thrombopoietin level measurements in thrombocytopenia. Thrombosis and Haemostasis, 79, 1101 1105.
60. Portielje, J.E., Westendorp, R.G., Kluin-Nelemans, H.C. Brand, A. (2001) Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood, 97, 2549 2554.
61. Provan, D., Butler, T., Evangelista, M.L., Amadori, S., Newland, A.C. Stasi, R. (2007) Activity and safety profile of low-dose rituximab for the treatment of autoimmune cytopenias in adults. Haematologica, 92, 1695 1698.
62. Rice, L., Nichol, J.L., McMillan, R., Roskos, L.K. Bacile, M. (2001) Cyclic immune thrombocytopenia responsive to thrombopoietic growth factor therapy. American Journal of Hematology, 68, 210 214.
63. Ruggeri, M., Fortuna, S. Rodeghiero, F. (2008) Heterogeneity of terminology and clinical definitions in adult idiopathic thrombocytopenic purpura: a critical appraisal from a systematic review of the literature. Haematologica, 93, 98 103.
64. de Sauvage, F.J., Hass, P.E., Spencer, S.D., Malloy, B.E., Gurney, A.L., Spencer, S.A., Darbonne, W.C., Henzel, W.J., Wong, S.C., Kuang, W.J., Oles, K.J., Hultgren, B., Solberg, L.A., Goeddel, D.V. Eaton, D.L. (1994) Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand. Nature, 369, 533 538.
65. Sayeh, E., Sterling, K., Speck, E., Freedman, J. Semple, J.W. (2004) IgG antiplatelet immunity is dependent on an early innate natural killer cell-derived interferon-gamma response that is regulated by CD8+ T cells. Blood, 103, 2705 2709.
66. Scaradavou, A., Woo, B., Woloski, B.M., Cunningham-Rundles, S., Ettinger, L.J., Aledort, L.M. Bussel, J.B. (1997) Intravenous anti-D treatment of immune thrombocytopenic purpura: experience in 272 patients. Blood, 89, 2689 2700.
67. Schwartz, J., Leber, M.D., Gillis, S., Giunta, A., Eldor, A. Bussel, J.B. (2003) Long term follow-up after splenectomy performed for immune thrombocytopenic purpura. American Journal of Hematology, 72, 94 98.
68. Stasi, R., Del Poeta, G., Stipa, E., Evangelista, M.L., Trawinska, M.M., Cooper, N. Amadori, S. (2007) Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura. Blood, 110, 2924 2930.
69. Stoll, D., Cines, D.B., Aster, R.H. Murphy, S. (1985) Platelet kinetics in patients with idiopathic thrombocytopenic purpura and moderate thrombocytopenia. Blood, 65, 584 588.
70. Teachey, D.T., Manno, C.S., Axsom, K.M., Andrews, T., Choi, J.K., Greenbaum, B.H., McMann, J.M., Sullivan, K.E., Travis, S.F. Grupp, S.A. (2005) Unmasking Evans syndrome: T cell phenotype and apoptotic response reveal autoimmune lymphoproliferative syndrome (ALPS). Blood, 105, 2443 2448.
71. Tremblay, T., Aubin, E., Lemieux, R. Bazin, R. (2007) Picogram doses of lipopolysaccharide exacerbate antibody-mediated thrombocytopenia and reduce the therapeutic efficacy of intravenous immunoglobulin in mice. British Journal Haematology, 139, 297 302.
72. Velanovich, V. Shurafa, M. (2000) Laparoscopic excision of accessory spleen. American Journal of Surgery, 180, 62 64.
73. Vesely, S.K., Perdue, J.J., Rizvi, M.A., Terrell, D.R. George, J.N. (2004) Management of adult patients with persistent idiopathic thrombocytopenic purpura following splenectomy: a systematic review. Annals of Internal Medicine, 140, 112 120.
74. Vianelli, N., Galli, M., de Vivo, A., Intermesoli, T., Giannini, B., Mazzucconi, M., Barbui, T., Tura, S., Baccaranion, M. for the Gruppo Italiano per lo Studio delle Malattie Ematologiche dell'Adulto. (2005) Efficacy and safety of splenectomy in immune thrombocytopenic purpura: long-term results of 402 cases. Haematologica, 90, 72 77.
75. Wang, B., Nichol, J.L. Sullivan, J.T. (2004) Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand. Clinical Pharmacology and Therapeutics, 76, 628 638.
76. Wendling, F., Maraskovsky, E., Debili, N., Florindo, C., Teepe, M., Titeux, M., Methia, N., Breton-Gorius, J., Cosman, D. Vainchenker, W. (1994) cMpl ligand is a humoral regulator of megakaryocytopoiesis. Nature, 369, 571 574.
77. Xiao, Y., Lin, W., Liu, Q., Jin, R. Fei, H. (2006) Direct infection of colony forming unit-megakaryocytes by human cytomegalovirus contributes the pathogenesis of idiopathic thrombocytopenic purpura. Journal of Huazhong University of Science and Technology. Medical Sciences, 26, 555 557.